Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Boundless Bio Inc BOLD

Healthcare Biotechnology
Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA (ecDNA) in the United States. The company lead product candidate is BBI-940, a ecDTx -directed therapeutic candidate that is in Phase 1/2 clinical trial in patients with breast cancer, triple – negative... see more

Recent & Breaking News (NDAQ:BOLD)

Boundless Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

GlobeNewswire 5 days ago

Boundless Bio to Participate in the Leerink Global Healthcare Conference

GlobeNewswire 10 days ago

Boundless Bio to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026

GlobeNewswire February 5, 2026

Boundless Bio Advances Novel Kinesin Degrader Program BBI-940 and Extends Cash Runway

GlobeNewswire January 20, 2026

Boundless Bio to Participate in the Piper Sandler 37th Annual Healthcare Conference

GlobeNewswire November 24, 2025

Boundless Bio Reports Third Quarter 2025 Financial Results and Business Highlights

GlobeNewswire November 5, 2025

Boundless Bio Announces Upcoming Presentation at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

GlobeNewswire October 13, 2025

Boundless Bio Reports Second Quarter 2025 Financial Results and Business Highlights

GlobeNewswire August 5, 2025

Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire June 5, 2025

Boundless Bio Announces Portfolio Prioritization and Runway Extension

GlobeNewswire May 23, 2025

Boundless Bio Reports First Quarter 2025 Financial Results and Business Highlights

GlobeNewswire May 9, 2025

Boundless Bio to Participate in the Needham Virtual Healthcare Conference

GlobeNewswire April 3, 2025

Boundless Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights

GlobeNewswire March 27, 2025

Boundless Bio to Participate in the Leerink Global Healthcare Conference

GlobeNewswire February 26, 2025

Boundless Bio Appoints Robert Doebele, M.D., Ph.D., as Chief Medical Officer

GlobeNewswire February 3, 2025

Boundless Bio Announces Pipeline and Leadership Updates

GlobeNewswire December 12, 2024

Boundless Bio to Participate in the Piper Sandler Healthcare Conference

GlobeNewswire November 25, 2024

Boundless Bio Reports Third Quarter 2024 Financial Results and Business Highlights

GlobeNewswire November 7, 2024

Boundless Bio to Participate in the 2024 Guggenheim Global Healthcare Conference

GlobeNewswire November 5, 2024

Boundless Bio Announces Departure of Chief Financial Officer

GlobeNewswire October 14, 2024

Podcasts